Expression of Bax, p53, and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis

被引:32
作者
Karlidag, Turgut [1 ]
Cobanoglu, Bengu
Keles, Erol
Alpay, Hayrettin Cengiz
Ozercan, Ibrahim
Kaygusuz, Irfan
Yalcin, Sinasi
Sakallioglu, Oner
机构
[1] Firat Univ, Fac Med, Dept Otorhinolaryngol, Elazig, Turkey
[2] Firat Univ, Fac Med, Dept Pathol, Elazig, Turkey
关键词
D O I
10.1016/j.amjoto.2006.06.008
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 [耳鼻咽喉科学];
摘要
Objective: The purpose of this study is to investigate the expression of Bax, p53, and p27/kip1 in patients with papillary thyroid carcinoma (PTC) with or without cervical nodal metastasis and to determine the role of immunohistochemical markers for prediction of neck metastasis in these patients. Study design and setting: A retrospective review from 1998 to 2004 at the Department of Otorhinolaryngology, Firat University, Elazig, Turkey, was performed in the records of 28 patients with nonmetastasizing (n = 15) and metastasizing (n = 13) PTC. The immunoreactivity, for Bax, p53, and p27/kip1 protein in all tissue specimens were assessed. Results: p27 expression in the nonmetastasizing PTC was lower than normal thyroid tissue (P <.01) and higher than metastasizing PTC (P <.01). p53 immunoreactivity was present, faint(grade 1) staining in a small number of cells in 2 nonmetastasizing PTCs. In 13 nonmetastasizing PTCs and all of metastasizing PTCs, normal thyroid tissue had no immunoreactivity for p53. There was no statistically significant difference among all groups' immunoreactivity for p53. Expression of Bax in patients with PTC was more than normal thyroid tissue (P <.01). However, expression of Bax in the patients with nonmetastasizing and metastasizing PTC was similar. Conclusion: The immunohistochemical evaluation of p27 expression in patients with PTC may be useful to predict for metastasis risk of the PTC to regional lymph nodes. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:31 / 36
页数:6
相关论文
共 27 条
[1]
Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer [J].
Beasley, NJP ;
Lee, J ;
Eski, S ;
Walfish, P ;
Witterick, I ;
Freeman, JL .
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2002, 128 (07) :825-828
[2]
A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma [J].
Bhattacharyya, N .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2003, 128 (01) :115-123
[3]
OVEREXPRESSION OF P53 AS A POSSIBLE PROGNOSTIC FACTOR IN HUMAN THYROID-CARCINOMA [J].
DOBASHI, Y ;
SAKAMOTO, A ;
SUGIMURA, H ;
MERNYEI, M ;
MORI, M ;
OYAMA, T ;
MACHINAMI, R .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1993, 17 (04) :375-381
[4]
GENE P53 MUTATIONS ARE RESTRICTED TO POORLY DIFFERENTIATED AND UNDIFFERENTIATED CARCINOMAS OF THE THYROID-GLAND [J].
DONGHI, R ;
LONGONI, A ;
PILOTTI, S ;
MICHIELI, P ;
DELLAPORTA, G ;
PIEROTTI, MA .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (04) :1753-1760
[5]
p27kip1 expression distinguishes papillary hyperplasia in Graves' disease from papillary thyroid carcinoma [J].
Erickson, LA ;
Yousef, OM ;
Jin, L ;
Lohse, CM ;
Pankratz, VS ;
Lloyd, RV .
MODERN PATHOLOGY, 2000, 13 (09) :1014-1019
[6]
Farid P, 2001, NEOPLASMA, V48, P299
[7]
Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma -: Inverse correlation with disease-free survival [J].
Florenes, VA ;
Mælandsmo, GM ;
Kerbel, RS ;
Slingerland, JM ;
Nesland, JM ;
Holm, R .
AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (01) :305-312
[8]
Prognostic factors in papillary and follicular thyroid carcinomas: p53 expression is a significant indicator of prognosis [J].
Godballe, C ;
Asschenfeldt, P ;
Jorgensen, KE ;
Bastholt, L ;
Clausen, PP ;
Hansen, TP ;
Hansen, O ;
Bentzen, SM .
LARYNGOSCOPE, 1998, 108 (02) :243-249
[9]
Grebe S K, 1996, Surg Oncol Clin N Am, V5, P43
[10]
MRI detection of cervical metastasis from differentiated thyroid carcinoma [J].
Gross, ND ;
Weissman, JL ;
Talbot, JM ;
Andersen, PE ;
Wax, MK ;
Cohen, JI .
LARYNGOSCOPE, 2001, 111 (11) :1905-1909